What is the appropriate emergency department treatment for acute sacroiliac joint pain?

Emergency Department Treatment for Acute Sacroiliac Joint Pain

For acute SI joint pain in the ED, initiate treatment with NSAIDs (ibuprofen 400-600 mg orally every 4-6 hours or any available NSAID) as first-line therapy, and consider ultrasound-guided intra-articular corticosteroid injection for patients with severe pain who have 3 or more positive provocative maneuvers on physical examination. 1, 2

Initial Assessment and Diagnosis

The SI joint accounts for 15-30% of chronic low back pain cases 3. In the ED setting, diagnosis relies on:

• Physical examination provocative tests: Patrick's Test, Thigh Thrust, Gaenslen's Test, Distraction, Compression, and Sacral Thrust
• Diagnostic threshold: When ≥3 of 6 tests are positive, sensitivity is 94% and specificity is 78% for SI joint pain 3
• With only 1-2 positive tests, specificity drops to 44-66%, making successful intervention less likely 3

Key clinical pearl: Patients with predisposing factors (pelvic trauma, spondyloarthritis, prior L5-S1 fusion) may warrant treatment with only 1-2 positive provocative maneuvers due to higher prevalence of SI joint pain in these populations 3.

Treatment Algorithm

Step 1: NSAID Therapy (First-Line)

• Ibuprofen 400-600 mg orally every 4-6 hours 1
• Alternative: Any other NSAID (naproxen, celecoxib) if ibuprofen unavailable 1
• For inflammatory sacroiliitis (spondyloarthropathy): NSAIDs are strongly recommended 4, 5

Step 2: Intra-articular Corticosteroid Injection (For Severe Pain)

Indications for ED injection 2:

• Significant pain causing functional limitation
• ≥3 positive provocative tests
• Patient is appropriate candidate for procedural intervention

Technique 3:

• Ultrasound-guided approach is feasible in the ED 2
• Fluoroscopy or CT guidance preferred when available 5
• Estimated joint volume: 1.4 mL (range 0.6-2.7 mL) 3
• Injectate: Local anesthetic + corticosteroid

Evidence supporting injection: Moderate-level evidence shows short-term effectiveness, with the only placebo-controlled RCT demonstrating 5 of 6 patients (83%) with spondyloarthropathy achieving >70% relief at 1 month versus 0% with placebo 3. Success rates are 50-72% when patients are properly selected 3, 6.

Step 3: Bridging Glucocorticoids (Conditional)

For patients with high disease activity, limited mobility, or significant symptoms, a short course (<3 months) of oral glucocorticoids may be considered during initiation of definitive therapy 4. However, long-term systemic glucocorticoids are strongly recommended against 5.

Important Caveats and Safety Considerations

Adverse events from SI joint injections 3:

• Most common: Injection-site soreness (13%), pain exacerbations (5%), vasovagal reactions (2.5%)
• Corticosteroid-specific: Facial flushing/sweating (2%)
• Transient sciatic nerve block (6% in some series) with fall risk—warn patients
• Bleeding risk is low; anticoagulation can typically be continued 3

When NOT to inject in the ED:

• Inability to perform adequate provocative testing
• <3 positive provocative maneuvers (unless high-risk population)
• Active infection or overlying cellulitis
• Lack of appropriate imaging guidance or procedural expertise

Disposition and Follow-up

• Pain duration >1 month with intensity >4/10: Ideal candidates for outpatient interventional pain referral 3
• Conservative therapy trial: Over-the-counter medications and physical therapy should be attempted before or concurrent with specialist referral 3
• Repeat injection criteria: May be appropriate if ≥75% relief from diagnostic injection, or ≥50% relief lasting ≥2 months 3

Evidence Quality Note

The evidence for ED-based SI joint injection is emerging 2, while the broader literature on image-guided SI joint injections shows moderate-quality evidence for short-term pain relief 3. The 2025 BMJ guideline on spine interventions 7 shows significant controversy in the field, with different societies providing contradictory recommendations. However, for acute presentations with clear clinical findings, the risk-benefit ratio favors intervention in appropriately selected patients.

Bottom line: NSAIDs are the foundation of ED treatment. For patients with severe pain and strong clinical evidence of SI joint dysfunction (≥3 positive tests), ultrasound-guided injection can provide meaningful short-term relief and is feasible in the ED setting 2.